ATE478859T1 - Pyrazolderivat - Google Patents

Pyrazolderivat

Info

Publication number
ATE478859T1
ATE478859T1 AT04708886T AT04708886T ATE478859T1 AT E478859 T1 ATE478859 T1 AT E478859T1 AT 04708886 T AT04708886 T AT 04708886T AT 04708886 T AT04708886 T AT 04708886T AT E478859 T1 ATE478859 T1 AT E478859T1
Authority
AT
Austria
Prior art keywords
compounds
salts
solvates
hydrates
pyrazole derivative
Prior art date
Application number
AT04708886T
Other languages
English (en)
Inventor
Naoaki Kanaya
Hiroaki Ishihara
Youichi Kimura
Takashi Ishiyama
Yuichi Ochiai
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ATE478859T1 publication Critical patent/ATE478859T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04708886T 2003-02-07 2004-02-06 Pyrazolderivat ATE478859T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003031639 2003-02-07
JP2003386515 2003-11-17
PCT/JP2004/001259 WO2004069824A1 (ja) 2003-02-07 2004-02-06 ピラゾール誘導体

Publications (1)

Publication Number Publication Date
ATE478859T1 true ATE478859T1 (de) 2010-09-15

Family

ID=32852694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708886T ATE478859T1 (de) 2003-02-07 2004-02-06 Pyrazolderivat

Country Status (15)

Country Link
US (1) US7622471B2 (de)
EP (1) EP1591443B1 (de)
JP (1) JPWO2004069824A1 (de)
KR (1) KR20050096956A (de)
AT (1) ATE478859T1 (de)
AU (1) AU2004209495A1 (de)
CA (1) CA2515119A1 (de)
DE (1) DE602004028800D1 (de)
IL (1) IL169709A0 (de)
MX (1) MXPA05008367A (de)
NO (1) NO20053648L (de)
PL (1) PL377848A1 (de)
RU (1) RU2332412C2 (de)
TW (1) TW200505447A (de)
WO (1) WO2004069824A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
CN1980912A (zh) * 2004-07-01 2007-06-13 第一制药株式会社 吡唑衍生物
EP1775293A4 (de) * 2004-08-06 2009-09-16 Daiichi Seiyaku Co Antithrombozytenmittel und verfahren zu dessen herstellung
RU2007108296A (ru) * 2004-08-06 2008-09-20 Дайити Фармасьютикал Ко., Лтд. (JP) Производные пиразола
GB0417910D0 (en) * 2004-08-11 2004-09-15 Novartis Ag Organic compounds
ZA200703562B (en) * 2004-10-19 2008-08-27 Daiichi Seiyaku Co 1,5-diheterocycle-1H-triazole derivative
JP2009184925A (ja) * 2006-11-02 2009-08-20 Dai Ichi Seiyaku Co Ltd 5−(1h−1,2,3−トリアゾール−4−イル)−1h−ピラゾール誘導体
GB0625196D0 (en) * 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
JP2013023477A (ja) * 2011-07-22 2013-02-04 Sagami Chemical Research Institute 4−トリフルオロメチルアゾール類の製造方法
BR112014006940A2 (pt) 2011-09-23 2017-04-04 Bayer Ip Gmbh uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
DE102011055815A1 (de) * 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
KR102318498B1 (ko) 2013-06-24 2021-10-27 메르크 파텐트 게엠베하 Fshr의 조절인자로서의 피라졸 화합물 및 이의 용도
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
WO2015196335A1 (en) 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (de) * 2018-04-04 2021-12-22 Japan Tobacco Inc. Heteroarylsubstituierte pyrazolverbindung und ihre medizinische verwendung
RU2716597C1 (ru) * 2019-11-29 2020-03-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Производные 2-(хромено[4,3-d]пиримидин-5-ил)уксусной кислоты и способ их получения
JP2023536442A (ja) 2020-07-29 2023-08-25 江蘇恒瑞医薬股▲ふん▼有限公司 オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
JP2025526688A (ja) * 2022-08-10 2025-08-15 ベットーレ リミテッド ライアビリティー カンパニー 疾患を治療するためのモノカルボン酸トランスポータ4の複素環式阻害剤の塩

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH587836A5 (de) 1974-01-31 1977-05-13 Serono Lab
JPS6140266A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
JPS62187467A (ja) 1986-02-12 1987-08-15 Mitsui Toatsu Chem Inc 4−アセチルイソキノリノン化合物の新規製造法
DE3808896A1 (de) * 1988-03-17 1989-09-28 Hoechst Ag Pflanzenschuetzende mittel auf basis von pyrazolcarbonsaeurederivaten
US5229386A (en) * 1989-01-05 1993-07-20 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US5217971A (en) * 1989-01-05 1993-06-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1993014062A1 (en) 1992-01-16 1993-07-22 The Upjohn Company ANTHELMINTIC β-KETOAMIDES
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
JPH0812654A (ja) 1994-06-27 1996-01-16 Sankyo Co Ltd 4−ハロピラゾール−3−カルボン酸誘導体
JPH08134041A (ja) * 1994-11-10 1996-05-28 Fuji Photo Film Co Ltd ピラゾールアミド類の製造方法
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JP3994453B2 (ja) 1995-10-13 2007-10-17 日産化学工業株式会社 ピラゾロン類
JPH09227555A (ja) 1996-02-16 1997-09-02 Taisho Pharmaceut Co Ltd チエニルピラゾール誘導体
US5854265A (en) * 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
CA2249665A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997049698A1 (en) * 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
EP1019394A1 (de) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLDERIVATE ALS p38-KINASE-INHIBITOREN
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6436966B1 (en) * 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
WO1999051580A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
EP1077971A1 (de) 1998-05-14 2001-02-28 G.D. SEARLE & CO. Substituierte 1,5-diarylpyrazole als p38 kinase inhibitoren
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
WO2001010865A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
OA12100A (en) 1999-12-03 2006-05-04 Pfizer Prod Inc Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents.
CA2326970C (en) 1999-12-03 2004-11-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1142889A1 (de) 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazolderivate als entzündungs-/schmerzhemmende Mittel
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
JP4759207B2 (ja) 2000-05-15 2011-08-31 あすか製薬株式会社 1−(ベンゾチアゾール−2−イル)ピラゾール誘導体およびそれを含有するcox−2阻害剤
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
WO2002067683A1 (en) 2001-02-26 2002-09-06 Merck & Co., Inc. Hiv protease inhibitors supported on cation exchange resins for oral administration
CN1259316C (zh) 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
WO2002092573A2 (en) * 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
JP2005022972A (ja) 2001-05-16 2005-01-27 Teikoku Hormone Mfg Co Ltd 4−(4−ピリダジニル)ピラゾール誘導体
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
EP1458374A2 (de) 2001-12-14 2004-09-22 Novo Nordisk A/S Verbindungen und deren verwendung zur senkung der aktivität der hormon-abhängigen lipase
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
ES2379076T3 (es) 2002-12-02 2012-04-20 Astellas Pharma Inc. Derivados de pirazol útiles como inhibidores de COX-I
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
KR20060005378A (ko) * 2003-04-21 2006-01-17 다이이찌 세이야꾸 가부시기가이샤 5원 복소환 유도체
JP2007084437A (ja) 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体

Also Published As

Publication number Publication date
KR20050096956A (ko) 2005-10-06
JPWO2004069824A1 (ja) 2006-05-25
WO2004069824A1 (ja) 2004-08-19
HK1087402A1 (zh) 2006-10-13
PL377848A1 (pl) 2006-02-20
US7622471B2 (en) 2009-11-24
EP1591443A1 (de) 2005-11-02
EP1591443A4 (de) 2007-09-12
CA2515119A1 (en) 2004-08-19
MXPA05008367A (es) 2005-11-04
EP1591443B1 (de) 2010-08-25
NO20053648D0 (no) 2005-07-27
NO20053648L (no) 2005-11-01
TW200505447A (en) 2005-02-16
AU2004209495A1 (en) 2004-08-19
RU2332412C2 (ru) 2008-08-27
DE602004028800D1 (en) 2010-10-07
RU2005127873A (ru) 2006-02-10
US20060128685A1 (en) 2006-06-15
IL169709A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
ATE478859T1 (de) Pyrazolderivat
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
MY153023A (en) Tropane derivatives useful in therapy
MY149038A (en) Cinnamide compound
MY150781A (en) Phthalazine derivatives as parp inhibitors
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20060219L (no) Forbindelser
ATE302775T1 (de) Carbolinderivate
ATE220066T1 (de) Benzimidazole derivate als cyclooxygenase-2 inhibitoren
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
TW200504049A (en) 5-memtered heterocyclic derivatives
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
EA200601076A1 (ru) Применение производных n-арилгидразина для борьбы с вредителями
EP1714961A4 (de) Indazolverbindung und deren pharmazeutische verwendung
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
MX2007004643A (es) Derivado de 1,5-diheterociclo-1h-triazol.
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
ATE360422T1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
EP1433479A4 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie
NO20054086L (no) Depigmenteringsmidler
MX2007012386A (es) 7-fluoro-1,3-dihidro-indol-2-ona oxazolidinonas como agentes antibacterianos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties